✦ LIBER ✦

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

✍ Scribed by Van Poppel, H.; Rathkopf, D.; Smith, M.R.; De Bono, J.S.; Logothetis, C.J.; Shore, N.D.; De Souza, P.; Fizazi, K.; Mulders, P.F.A.; Mainwaring, P.; Hainsworth, J.D.; Beer, T.M.; North, S.; Fradet, Y.; Griffin, T.; Park, Y.C.; Kheoh, T.; Small, E.J.; Scher, H.I.; Molina, A.; Ryan, C.J.

Book ID: 122545646
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 109 KB
Volume: 12
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(13)60589-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

713 ABIRATERONE ACETATE IN METASTATIC CA

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

✍ Saad, Fred; Shore, Neal D; Van Poppel, Hendrik; Rathkopf, Dana; Smith, Matthew R 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 51 KB

Updated Interim Efficacy Analysis and Lo

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

✍ Rathkopf, Dana E.; Smith, Matthew R.; de Bono, Johann S.; Logothetis, Christophe 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 987 KB

105 Exploratory analysis of the visceral

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

✍ Suttmann, H.; Mulders, P.F.A.; Molina, A.; Goodman, O.B.; Flaig, T.W.; Li, J.; K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

MP70-11 IMPACT OF PRIOR ENDOCRINE THERAP

MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302

✍ Saad, Fred; Kheoh, Thian; Yu, Margaret K.; Smith, Matthew R.; Small, Eric J.; Mu 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 146 KB

7000 ORAL Final Overall Survival (OS) An

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

✍ Fizazi, K.; Scher, H.I.; Molina, A.; Logothetis, C.J.; Jones, R.J.; Staffurth, J 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

127 Improved survival in elderly (≥75 yr

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study

✍ P.F.A. Mulders; A. Molina; M. Marberger; F. Saad; J.H. Li; T. Kheoh; C.M. Haqq; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB